NATCO Pharma Limited has been in focus on Thursday after the company announced its financial results for the third quarter of the financial year 2025.
On February 13, 2025, NATCO Pharma share price (NSE: NATCOPHARM) opened at ₹1,039.10, down from its previous close of ₹1,218.80. At 10:43 AM, the share price of NATCO Pharma was trading at ₹991.30, down by 18.67% on the NSE. As of the same time, the stock price touched its day’s low so far at ₹986.55.
The company reported a consolidated total revenue of ₹651.1 crore for the quarter ended December 31, 2024. This marks a decline from ₹795.6 crore recorded in the same period last year. The drop in revenue was attributed to lower contributions from the export formulation business, though NATCO remains optimistic about future growth in the upcoming quarters.
In terms of revenue segmentation, Pharma Export Formulations contributed ₹285.8 crore, while Domestic Formulations Revenue stood at ₹96.1 crore.
The company’s net profit for Q3 FY25 stood at ₹132.4 crore, compared to ₹212.7 crore in Q3 FY24.
Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) for the quarter stood at ₹215.1 crore, with an EBITDA margin of 33%.
NATCO Pharma’s Board of Directors declared a third interim dividend of ₹1.50 per equity share (75% of the face value of ₹2 per share) for the financial year 2024-25. The record date for determining eligible shareholders has been set for Tuesday, February 18, 2025. The payment of the interim dividend is scheduled to commence from February 28, 2025.
NATCO Pharma Limited, headquartered in Hyderabad, India, specialises in the development, manufacturing, and distribution of generic and branded pharmaceuticals, speciality drugs, active pharmaceutical ingredients, and crop protection products.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 13, 2025, 11:22 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
